Form 4: Sagimet Biosciences Director Sells Shares
Insider Transaction (Form 4)
George Kemble, a Director of Sagimet Biosciences Inc., sold 20,206 shares of common stock on August 11, 2026 for $9.95 per share.
Summary
- Option exercise/conversion: acquired 9,751 Series A Common Stock at $6.36 ($62,016) on August 11, 2026; holds 71,912 after (Direct).
- Option exercise/conversion: acquired 10,455 Series A Common Stock at $6.36 ($66,494) on August 11, 2026; holds 82,367 after (Direct).
- Open-market sale: disposed of 20,206 Series A Common Stock at $9.95 ($201,147) on August 11, 2026; holds 62,161 after (Direct).
- Option exercise/conversion: disposed of 9,751 Stock Option (Right to Buy) on August 11, 2026; holds 358,073 after (Direct).
- Option exercise/conversion: disposed of 10,455 Stock Option (Right to Buy) on August 11, 2026; holds 35,977 after (Direct).
Sentiment
Score: 4
Explanation: StockSavvy.ai views this as a mildly negative but low-conviction signal: an insider sold $201,147 of stock under a pre-arranged Rule 10b5-1 plan, which is typically routine.
Insider Transactions
George Kemble — Director
Transaction made under a Rule 10b5-1 trading plan.
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-08-11 | Option exercise/conversion | Series A Common Stock | 9,751 | $6 | $62.0K | 71,912 |
| 2026-08-11 | Option exercise/conversion | Series A Common Stock | 10,455 | $6 | $66.5K | 82,367 |
| 2026-08-11 | Open-market sale | Series A Common Stock | 20,206 | $10 | $201.1K | 62,161 |
| 2026-08-11 | Option exercise/conversion | Stock Option (Right to Buy) | 9,751 | — | — | 358,073 |
| 2026-08-11 | Option exercise/conversion | Stock Option (Right to Buy) | 10,455 | — | — | 35,977 |
Key Dates
| Date | Description |
|---|---|
| 2026-08-11 | Option exercise/conversion (9,751 shares) |
| 2026-08-11 | Option exercise/conversion (10,455 shares) |
| 2026-08-11 | Open-market sale (20,206 shares) |
| 2026-08-11 | Option exercise/conversion (9,751 shares) |
| 2026-08-11 | Option exercise/conversion (10,455 shares) |
Keywords
insider transaction, Form 4, SGMT, Sagimet Biosciences Inc., bearish, George Kemble
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.